Literature DB >> 12182930

Depression in Alzheimer's disease: overview and treatment.

Constantine G Lyketsos1, Jason Olin.   

Abstract

Psychiatric disturbances affect as many as 90% of patients with Alzheimer's disease (AD) and are a major focus of treatment. Depression is one of the most frequent psychiatric complications of AD, affecting as many as 50% of patients. In this context, depression is a significant public health problem that has a series of serious adverse consequences for patients and their caregivers. There has been little research into the course or treatment of depression associated with AD. This is in part due to the absence of validated operational criteria for defining depression in AD. Recently, the National Institute of Mental Health (NIMH) convened an expert consensus panel to develop draft criteria for depression of Alzheimer's disease (NIMH-dAD) and to establish research priorities in this area. This article provides an overview of recent knowledge with regard to depression in AD with a special emphasis on its treatment. We conclude with recommendations for further research in this area.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182930     DOI: 10.1016/s0006-3223(02)01348-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  67 in total

1.  Alzheimer's therapies.

Authors:  Elisa F Cascade; Amir H Kalali; Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2007-08

2.  Mental illness training for licensed staff in long-term care.

Authors:  A Blair Irvine; Molly B Billow; Mark G Eberhage; John R Seeley; Edward McMahon; Michelle Bourgeois
Journal:  Issues Ment Health Nurs       Date:  2012-03       Impact factor: 1.835

3.  Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study.

Authors:  C Arbus; V Gardette; C E Cantet; S Andrieu; F Nourhashémi; L Schmitt; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

4.  Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction.

Authors:  Paul B Rosenberg; Michelle M Mielke; Brian Appleby; Esther Oh; Jeannie-Marie Leoutsakos; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2010-09-15       Impact factor: 3.485

5.  Clinicopathological correlates of depression in early Alzheimer's disease in the NACC.

Authors:  Sarah T McCutcheon; Dingfen Han; Juan Troncoso; Vassilis E Koliatsos; Marilyn Albert; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos
Journal:  Int J Geriatr Psychiatry       Date:  2016-02-14       Impact factor: 3.485

6.  Sertraline for the treatment of depression in Alzheimer disease.

Authors:  Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-02       Impact factor: 4.105

7.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

Review 8.  Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms.

Authors:  Jeannie Chin; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-13       Impact factor: 2.937

9.  Anxiety and verbal memory performance in APOE-4 carriers and noncarriers aged 50 years and above.

Authors:  Ashley R Curiel; Karen J Miller; Karen Pollard; Jeanne Kim; Jena Kravitz; Gary W Small
Journal:  Aging health       Date:  2012-02-01

10.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.